title: Acanthamoeba keratitis: clinical characteristics and management.
abstract: OBJECTIVE
  To review the clinical characteristics, treatment, and outcome of patients with Acanthamoeba keratitis (AK).
  
  
  METHODS
  Retrospective, noncomparative, interventional case series.
  
  
  METHODS
  Twenty consecutive patients with AK were referred to the Beijing Tongren Hospital, Capital University of Medical Science, China.
  
  
  METHODS
  Retrospective analysis of medical records from 20 consecutive patients with AK between December 1, 1997 and March 30, 2003. Risk factors, laboratory investigations, clinical manifestations, treatments, and outcomes were analyzed.
  
  
  METHODS
  Best-corrected visual acuity (BCVA) at the end of follow-up.
  
  
  RESULTS
  Of the 20 patients presented in this series, 12 patients were students and 6 were farmers. Risk factors included contact lens wear (12/20) and trauma (6/20). Corneal ulceration, diffuse stromal infiltration, and ring infiltration were the main clinical manifestations. The diagnosis of all patients was based on the laboratory investigation. Smear and culture positive specimens were 19 of 20 and 12 of 20, respectively. Images of cysts were demonstrated with confocal microscopy in 4 patients. Treatment was combined instillation of chlorhexidine (0.02%), neomycin (0.5%), metronidazole (0.4%), and/or lesion cauterization with chlorhexidine (1%), and corneal lesion debridement. The mean duration of therapy was 70 days (range, 18-150 days). Nineteen lesions healed with scar formation. The BCVA was better or equal to 20/100 in 7 eyes.
  
  
  CONCLUSIONS
  Early diagnosis of AK is the key challenge in clinical practice. The combined use of antiacanthamoeba agents, debridement, and cauterization may be a best choice of treatment for patients who are diagnosed early in the course of their disease.
authors.affiliation: Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital University of Medical Science, Beijing, China. sunxuguang@yahoo.com
authors.forename: Xuguang
authors.initials: X
authors.lastname: Sun
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Ran
authors.initials: R
authors.lastname: Li
authors.forename: Zhiqun
authors.initials: Z
authors.lastname: Wang
authors.forename: Shiyun
authors.initials: S
authors.lastname: Luo
authors.forename: Min
authors.initials: M
authors.lastname: Gao
authors.forename: Shijing
authors.initials: S
authors.lastname: Deng
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Xiuying
authors.initials: X
authors.lastname: Jin
mesh_terms: D015823:Acanthamoeba Keratitis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D000293:Adolescent; D000328:Adult; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002425:Cautery; D002648:Child; D002710:Chlorhexidine / Q000008:administration & dosage / Q000627:therapeutic use; D003646:Debridement; D004338:Drug Combinations; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009355:Neomycin / Q000008:administration & dosage / Q000627:therapeutic use; D009883:Ophthalmic Solutions; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000891:Anti-Infective Agents, Local; D000981:Antiprotozoal Agents; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D008795:Metronidazole; D009355:Neomycin; D002710:Chlorhexidine